▶ 調査レポート

世界の心血管疾患治療用タンパク質市場 2021:企業別、地域別、種類・用途別

• 英文タイトル:Global Therapeutic Proteins for Cardiovascular Disorders Treatment Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026

GlobalInfoResearchが調査・発行した産業分析レポートです。世界の心血管疾患治療用タンパク質市場 2021:企業別、地域別、種類・用途別 / Global Therapeutic Proteins for Cardiovascular Disorders Treatment Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026 / GIR-107A14776資料のイメージです。• レポートコード:GIR-107A14776
• 出版社/出版日:GlobalInfoResearch / 2021年7月
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、107ページ
• 納品方法:Eメール(納期:2~3日)
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥515,040 (USD3,480)▷ お問い合わせ
  Multi User¥772,560 (USD5,220)▷ お問い合わせ
  Corporate User¥1,030,080 (USD6,960)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査資料では、心血管疾患治療用タンパク質のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。心血管疾患治療用タンパク質の種類別市場規模(モノクローナル抗体タンパク質、ペプチドタンパク質、ペプチドフラグメントタンパク質)、用途別市場規模(心不全、心筋梗塞、不整脈、冠状動脈疾患、虚血性心疾患)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。
・心血管疾患治療用タンパク質の市場概要
・企業情報(企業概要、製品概要、販売量、価格、売上):Johnson & Johnson、Eli Lilly & Company、Roche、Pfizer、Bristol Myers Squibb、Sanofi、Merck、Amgen、Novartis、Siemens Healthineers
・企業別市場シェア
・地域別市場分析2016年-2026年
・種類別分析2016年-2026年:モノクローナル抗体タンパク質、ペプチドタンパク質、ペプチドフラグメントタンパク質
・用途別分析2016年-2026年:心不全、心筋梗塞、不整脈、冠状動脈疾患、虚血性心疾患
・心血管疾患治療用タンパク質の北米市場規模2016年-2026年:アメリカ、カナダ、メキシコ
・心血管疾患治療用タンパク質のヨーロッパ市場規模2016年-2026年:ドイツ、イギリス、フランス、ロシア、イタリア
・心血管疾患治療用タンパク質のアジア市場規模2016年-2026年:中国、日本、韓国、インド、東南アジア、オーストラリア
・心血管疾患治療用タンパク質の南米市場規模2016年-2026年:ブラジル、アルゼンチン
・心血管疾患治療用タンパク質の中東・アフリカ市場規模2016年-2026年:サウジアラビア、トルコ、エジプト、南アフリカ
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Therapeutic Proteins for Cardiovascular Disorders Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Therapeutic Proteins for Cardiovascular Disorders Treatment size is estimated to be xx million in 2021 from USD xx million in 2020, with a change of XX% between 2020 and 2021. The global Therapeutic Proteins for Cardiovascular Disorders Treatment market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Therapeutic Proteins for Cardiovascular Disorders Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Monoclonal Antibodies Proteins
Peptides Proteins
Peptide Fragments Proteins

Market segment by Application can be divided into
Heart Failure
Myocardial Infarction
Arrhythmias
Coronary Artery Disease
Ischemic Heart Disease

The key market players for global Therapeutic Proteins for Cardiovascular Disorders Treatment market are listed below:
Johnson & Johnson
Eli Lilly & Company
Roche
Pfizer
Bristol Myers Squibb
Sanofi
Merck
Amgen
Novartis
Siemens Healthineers

Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Therapeutic Proteins for Cardiovascular Disorders Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Therapeutic Proteins for Cardiovascular Disorders Treatment, with price, sales, revenue and global market share of Therapeutic Proteins for Cardiovascular Disorders Treatment in 2018 and 2019.
Chapter 3, the Therapeutic Proteins for Cardiovascular Disorders Treatment competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Therapeutic Proteins for Cardiovascular Disorders Treatment breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Therapeutic Proteins for Cardiovascular Disorders Treatment market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Therapeutic Proteins for Cardiovascular Disorders Treatment sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

1 Market Overview
1.1 Therapeutic Proteins for Cardiovascular Disorders Treatment Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Monoclonal Antibodies Proteins
1.2.3 Peptides Proteins
1.2.4 Peptide Fragments Proteins
1.3 Market Analysis by Application
1.3.1 Overview: Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Heart Failure
1.3.3 Myocardial Infarction
1.3.4 Arrhythmias
1.3.5 Coronary Artery Disease
1.3.6 Ischemic Heart Disease
1.4 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size & Forecast
1.4.1 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales in Value (2016-2026))
1.4.2 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales in Volume (2016-2026)
1.4.3 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Price by Type (2016-2026) & (USD/KG)
1.5 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Production Capacity Analysis
1.5.1 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Total Production Capacity (2016-2026)
1.5.2 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Therapeutic Proteins for Cardiovascular Disorders Treatment Market Drivers
1.6.2 Therapeutic Proteins for Cardiovascular Disorders Treatment Market Restraints
1.6.3 Therapeutic Proteins for Cardiovascular Disorders Treatment Trends Analysis
2 Manufacturers Profiles
2.1 Johnson & Johnson
2.1.1 Johnson & Johnson Details
2.1.2 Johnson & Johnson Major Business
2.1.3 Johnson & Johnson Therapeutic Proteins for Cardiovascular Disorders Treatment Product and Services
2.1.4 Johnson & Johnson Therapeutic Proteins for Cardiovascular Disorders Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 Eli Lilly & Company
2.2.1 Eli Lilly & Company Details
2.2.2 Eli Lilly & Company Major Business
2.2.3 Eli Lilly & Company Therapeutic Proteins for Cardiovascular Disorders Treatment Product and Services
2.2.4 Eli Lilly & Company Therapeutic Proteins for Cardiovascular Disorders Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 Roche
2.3.1 Roche Details
2.3.2 Roche Major Business
2.3.3 Roche Therapeutic Proteins for Cardiovascular Disorders Treatment Product and Services
2.3.4 Roche Therapeutic Proteins for Cardiovascular Disorders Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business
2.4.3 Pfizer Therapeutic Proteins for Cardiovascular Disorders Treatment Product and Services
2.4.4 Pfizer Therapeutic Proteins for Cardiovascular Disorders Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Bristol Myers Squibb
2.5.1 Bristol Myers Squibb Details
2.5.2 Bristol Myers Squibb Major Business
2.5.3 Bristol Myers Squibb Therapeutic Proteins for Cardiovascular Disorders Treatment Product and Services
2.5.4 Bristol Myers Squibb Therapeutic Proteins for Cardiovascular Disorders Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 Sanofi
2.6.1 Sanofi Details
2.6.2 Sanofi Major Business
2.6.3 Sanofi Therapeutic Proteins for Cardiovascular Disorders Treatment Product and Services
2.6.4 Sanofi Therapeutic Proteins for Cardiovascular Disorders Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.7 Merck
2.7.1 Merck Details
2.7.2 Merck Major Business
2.7.3 Merck Therapeutic Proteins for Cardiovascular Disorders Treatment Product and Services
2.7.4 Merck Therapeutic Proteins for Cardiovascular Disorders Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.8 Amgen
2.8.1 Amgen Details
2.8.2 Amgen Major Business
2.8.3 Amgen Therapeutic Proteins for Cardiovascular Disorders Treatment Product and Services
2.8.4 Amgen Therapeutic Proteins for Cardiovascular Disorders Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.9 Novartis
2.9.1 Novartis Details
2.9.2 Novartis Major Business
2.9.3 Novartis Therapeutic Proteins for Cardiovascular Disorders Treatment Product and Services
2.9.4 Novartis Therapeutic Proteins for Cardiovascular Disorders Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.10 Siemens Healthineers
2.10.1 Siemens Healthineers Details
2.10.2 Siemens Healthineers Major Business
2.10.3 Siemens Healthineers Therapeutic Proteins for Cardiovascular Disorders Treatment Product and Services
2.10.4 Siemens Healthineers Therapeutic Proteins for Cardiovascular Disorders Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Manufacturer
3.1 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Therapeutic Proteins for Cardiovascular Disorders Treatment
3.4 Market Concentration Rate
3.4.1 Top 3 Therapeutic Proteins for Cardiovascular Disorders Treatment Manufacturer Market Share
3.4.2 Top 6 Therapeutic Proteins for Cardiovascular Disorders Treatment Manufacturer Market Share
3.5 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Therapeutic Proteins for Cardiovascular Disorders Treatment Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size by Region
4.1.1 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales in Volume by Region (2016-2026)
4.1.2 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Region (2016-2026)
4.2 North America Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue (2016-2026)
4.3 Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue (2016-2026)
4.4 Asia-Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue (2016-2026)
4.5 South America Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue (2016-2026)
4.6 Middle East and Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales in Volume by Type (2016-2026)
5.2 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Type (2016-2026)
5.3 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales in Volume by Application (2016-2026)
6.2 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Application (2016-2026)
6.3 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Type (2016-2026)
7.2 North America Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Application (2016-2026)
7.3 North America Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size by Country
7.3.1 North America Therapeutic Proteins for Cardiovascular Disorders Treatment Sales in Volume by Country (2016-2026)
7.3.2 North America Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Type (2016-2026)
8.2 Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Application (2016-2026)
8.3 Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size by Country
8.3.1 Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Sales in Volume by Country (2016-2026)
8.3.2 Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Type (2016-2026)
9.2 Asia-Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Application (2016-2026)
9.3 Asia-Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size by Region
9.3.1 Asia-Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Type (2016-2026)
10.2 South America Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Application (2016-2026)
10.3 South America Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size by Country
10.3.1 South America Therapeutic Proteins for Cardiovascular Disorders Treatment Sales in Volume by Country (2016-2026)
10.3.2 South America Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Type (2016-2026)
11.2 Middle East & Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Application (2016-2026)
11.3 Middle East & Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size by Country
11.3.1 Middle East & Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Therapeutic Proteins for Cardiovascular Disorders Treatment Typical Distributors
12.3 Therapeutic Proteins for Cardiovascular Disorders Treatment Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

List of Tables
Table 1. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Type, (USD Million), 2021-2026
Table 2. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Application, (USD Million), 2021-2026
Table 3. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 4. Johnson & Johnson Major Business
Table 5. Johnson & Johnson Therapeutic Proteins for Cardiovascular Disorders Treatment Product and Services
Table 6. Johnson & Johnson Therapeutic Proteins for Cardiovascular Disorders Treatment Sales (KG), Price (USD/KG), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Eli Lilly & Company Basic Information, Manufacturing Base and Competitors
Table 8. Eli Lilly & Company Major Business
Table 9. Eli Lilly & Company Therapeutic Proteins for Cardiovascular Disorders Treatment Product and Services
Table 10. Eli Lilly & Company Therapeutic Proteins for Cardiovascular Disorders Treatment Sales (KG), Price (USD/KG), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Roche Basic Information, Manufacturing Base and Competitors
Table 12. Roche Major Business
Table 13. Roche Therapeutic Proteins for Cardiovascular Disorders Treatment Product and Services
Table 14. Roche Therapeutic Proteins for Cardiovascular Disorders Treatment Sales (KG), Price (USD/KG), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Pfizer Basic Information, Manufacturing Base and Competitors
Table 16. Pfizer Major Business
Table 17. Pfizer Therapeutic Proteins for Cardiovascular Disorders Treatment Product and Services
Table 18. Pfizer Therapeutic Proteins for Cardiovascular Disorders Treatment Sales (KG), Price (USD/KG), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Bristol Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 20. Bristol Myers Squibb Major Business
Table 21. Bristol Myers Squibb Therapeutic Proteins for Cardiovascular Disorders Treatment Product and Services
Table 22. Bristol Myers Squibb Therapeutic Proteins for Cardiovascular Disorders Treatment Sales (KG), Price (USD/KG), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Sanofi Basic Information, Manufacturing Base and Competitors
Table 24. Sanofi Major Business
Table 25. Sanofi Therapeutic Proteins for Cardiovascular Disorders Treatment Product and Services
Table 26. Sanofi Therapeutic Proteins for Cardiovascular Disorders Treatment Sales (KG), Price (USD/KG), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Merck Basic Information, Manufacturing Base and Competitors
Table 28. Merck Major Business
Table 29. Merck Therapeutic Proteins for Cardiovascular Disorders Treatment Product and Services
Table 30. Merck Therapeutic Proteins for Cardiovascular Disorders Treatment Sales (KG), Price (USD/KG), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Amgen Basic Information, Manufacturing Base and Competitors
Table 32. Amgen Major Business
Table 33. Amgen Therapeutic Proteins for Cardiovascular Disorders Treatment Product and Services
Table 34. Amgen Therapeutic Proteins for Cardiovascular Disorders Treatment Sales (KG), Price (USD/KG), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Novartis Basic Information, Manufacturing Base and Competitors
Table 36. Novartis Major Business
Table 37. Novartis Therapeutic Proteins for Cardiovascular Disorders Treatment Product and Services
Table 38. Novartis Therapeutic Proteins for Cardiovascular Disorders Treatment Sales (KG), Price (USD/KG), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 39. Siemens Healthineers Basic Information, Manufacturing Base and Competitors
Table 40. Siemens Healthineers Major Business
Table 41. Siemens Healthineers Therapeutic Proteins for Cardiovascular Disorders Treatment Product and Services
Table 42. Siemens Healthineers Therapeutic Proteins for Cardiovascular Disorders Treatment Sales (KG), Price (USD/KG), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 43. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Manufacturer (2019-2021e) & (KG)
Table 44. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 45. Market Position of Manufacturers in Therapeutic Proteins for Cardiovascular Disorders Treatment, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 46. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Production Capacity by Company, (KG): 2020 VS 2021
Table 47. Head Office and Therapeutic Proteins for Cardiovascular Disorders Treatment Production Site of Key Manufacturer
Table 48. Therapeutic Proteins for Cardiovascular Disorders Treatment New Entrant and Capacity Expansion Plans
Table 49. Therapeutic Proteins for Cardiovascular Disorders Treatment Mergers & Acquisitions in the Past Five Years
Table 50. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Region (2016-2021e) & (KG)
Table 51. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Region (2021-2026) & (KG)
Table 52. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Region (2016-2021e) & (USD Million)
Table 53. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Region (2021-2026) & (USD Million)
Table 54. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Type (2016-2021e) & (KG)
Table 55. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Type (2021-2026) & (KG)
Table 56. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Type (2016-2021e) & (USD Million)
Table 57. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Type (2021-2026) & (USD Million)
Table 58. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Price by Type (2016-2021e) & (USD/KG)
Table 59. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Price by Type (2021-2026) & (USD/KG)
Table 60. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Application (2016-2021e) & (KG)
Table 61. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Application (2021-2026) & (KG)
Table 62. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Application (2016-2021e) & (USD Million)
Table 63. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Application (2021-2026) & (USD Million)
Table 64. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Price by Application (2016-2021e) & (USD/KG)
Table 65. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Price by Application (2021-2026) & (USD/KG)
Table 66. North America Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Country (2016-2021e) & (KG)
Table 67. North America Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Country (2021-2026) & (KG)
Table 68. North America Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Country (2016-2021e) & (USD Million)
Table 69. North America Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Country (2021-2026) & (USD Million)
Table 70. North America Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Type (2016-2021e) & (KG)
Table 71. North America Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Type (2021-2026) & (KG)
Table 72. North America Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Application (2016-2021e) & (KG)
Table 73. North America Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Application (2021-2026) & (KG)
Table 74. Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Country (2016-2021e) & (KG)
Table 75. Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Country (2021-2026) & (KG)
Table 76. Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Country (2016-2021e) & (USD Million)
Table 77. Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Country (2021-2026) & (USD Million)
Table 78. Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Type (2016-2021e) & (KG)
Table 79. Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Type (2021-2026) & (KG)
Table 80. Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Application (2016-2021e) & (KG)
Table 81. Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Application (2021-2026) & (KG)
Table 82. Asia-Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Region (2016-2021e) & (KG)
Table 83. Asia-Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Region (2021-2026) & (KG)
Table 84. Asia-Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Region (2016-2021e) & (USD Million)
Table 85. Asia-Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Region (2021-2026) & (USD Million)
Table 86. Asia-Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Type (2016-2021e) & (KG)
Table 87. Asia-Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Type (2021-2026) & (KG)
Table 88. Asia-Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Application (2016-2021e) & (KG)
Table 89. Asia-Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Application (2021-2026) & (KG)
Table 90. South America Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Country (2016-2021e) & (KG)
Table 91. South America Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Country (2021-2026) & (KG)
Table 92. South America Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Country (2016-2021e) & (USD Million)
Table 93. South America Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Country (2021-2026) & (USD Million)
Table 94. South America Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Type (2016-2021e) & (KG)
Table 95. South America Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Type (2021-2026) & (KG)
Table 96. South America Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Application (2016-2021e) & (KG)
Table 97. South America Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Application (2021-2026) & (KG)
Table 98. Middle East & Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Country (2016-2021e) & (KG)
Table 99. Middle East & Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Country (2021-2026) & (KG)
Table 100. Middle East & Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Country (2016-2021e) & (USD Million)
Table 101. Middle East & Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Country (2021-2026) & (USD Million)
Table 102. Middle East & Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Type (2016-2021e) & (KG)
Table 103. Middle East & Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Type (2021-2026) & (KG)
Table 104. Middle East & Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Application (2016-2021e) & (KG)
Table 105. Middle East & Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Application (2021-2026) & (KG)
Table 106. Direct Channel Pros & Cons
Table 107. Indirect Channel Pros & Cons
Table 108. Therapeutic Proteins for Cardiovascular Disorders Treatment Typical Distributors
Table 109. Therapeutic Proteins for Cardiovascular Disorders Treatment Typical Customers
List of Figures
Figure 1. Therapeutic Proteins for Cardiovascular Disorders Treatment Picture
Figure 2. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Type in 2020
Figure 3. Monoclonal Antibodies Proteins
Figure 4. Peptides Proteins
Figure 5. Peptide Fragments Proteins
Figure 6. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Application in 2020
Figure 7. Heart Failure
Figure 8. Myocardial Infarction
Figure 9. Arrhythmias
Figure 10. Coronary Artery Disease
Figure 11. Ischemic Heart Disease
Figure 12. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size, (USD Million) & (KG): 2020 VS 2021 VS 2026
Figure 13. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size and Forecast (2016-2026) & (USD Million)
Figure 14. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales (2016-2026) & (KG)
Figure 15. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Price by Type (2016-2026) & (USD/KG)
Figure 16. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Production Capacity (2016-2026) & (KG)
Figure 17. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Production Capacity by Geographic Region: 2020 VS 2021
Figure 18. Therapeutic Proteins for Cardiovascular Disorders Treatment Market Drivers
Figure 19. Therapeutic Proteins for Cardiovascular Disorders Treatment Market Restraints
Figure 20. Therapeutic Proteins for Cardiovascular Disorders Treatment Market Trends
Figure 21. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Manufacturer in 2020
Figure 22. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Market Share by Manufacturer in 2020
Figure 23. Therapeutic Proteins for Cardiovascular Disorders Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 24. Top 3 Therapeutic Proteins for Cardiovascular Disorders Treatment Manufacturer (Revenue) Market Share in 2020
Figure 25. Top 6 Therapeutic Proteins for Cardiovascular Disorders Treatment Manufacturer (Revenue) Market Share in 2020
Figure 26. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Region (2016-2026)
Figure 27. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Market Share by Region (2016-2026)
Figure 28. North America Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue (2016-2026) & (USD Million)
Figure 29. Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue (2016-2026) & (USD Million)
Figure 30. Asia-Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue (2016-2026) & (USD Million)
Figure 31. South America Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue (2016-2026) & (USD Million)
Figure 32. Middle East & Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue (2016-2026) & (USD Million)
Figure 33. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Type (2016-2026)
Figure 34. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Market Share by Type (2016-2026)
Figure 35. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Price by Type (2016-2026) & (USD/KG)
Figure 36. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Application (2016-2026)
Figure 37. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Market Share by Application (2016-2026)
Figure 38. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Price by Application (2016-2026) & (USD/KG)
Figure 39. North America Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Type (2016-2026)
Figure 40. North America Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Application (2016-2026)
Figure 41. North America Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Country (2016-2026)
Figure 42. North America Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Market Share by Country (2016-2026)
Figure 43. United States Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. Canada Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Mexico Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Type (2016-2026)
Figure 47. Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Application (2016-2026)
Figure 48. Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Country (2016-2026)
Figure 49. Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Market Share by Country (2016-2026)
Figure 50. Germany Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. France Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. United Kingdom Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Russia Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Italy Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Asia-Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Region (2016-2026)
Figure 56. Asia-Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Application (2016-2026)
Figure 57. Asia-Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Region (2016-2026)
Figure 58. Asia-Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Market Share by Region (2016-2026)
Figure 59. China Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Japan Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Korea Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. India Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Southeast Asia Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Australia Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. South America Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Type (2016-2026)
Figure 66. South America Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Application (2016-2026)
Figure 67. South America Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Country (2016-2026)
Figure 68. South America Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Market Share by Country (2016-2026)
Figure 69. Brazil Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Argentina Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Middle East & Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Type (2016-2026)
Figure 72. Middle East & Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Application (2016-2026)
Figure 73. Middle East & Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Country (2016-2026)
Figure 74. Middle East & Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Market Share by Country (2016-2026)
Figure 75. Turkey Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Egypt Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Saudi Arabia Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. South Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. Sales Channel: Direct Channel vs Indirect Channel
Figure 80. Methodology
Figure 81. Research Process and Data Source